| Title: |
Rationale and design of ELIXIR, a randomized, controlled trial to evaluate efficacy and safety of XyloCore, a glucose-sparing solution for peritoneal dialysis |
| Authors: |
Mario Bonomini; Simon Davies; Mark Lambie; Werner Kleophas; Gianpaolo Reboldi; Lorenzo Di Liberato; Josè Carolino Divino-Filho; Olof Heimburger; Alberto Ortiz; Johan Povlsen; Massimo Iacobelli; Tommaso Prosdocimi; Arduino Arduini |
| Contributors: |
Bonomini, Mario; Davies, Simon; Lambie, Mark; Kleophas, Werner; Reboldi, Gianpaolo; Di Liberato, Lorenzo; Carolino Divino-Filho, Josè; Heimburger, Olof; Ortiz, Alberto; Povlsen, Johan; Iacobelli, Massimo; Prosdocimi, Tommaso; Arduini, Arduino |
| Publication Year: |
2025 |
| Collection: |
ARUd'A - Archivio Istituzionale della ricerca dell'università Chieti-Pescara (IRIS) |
| Subject Terms: |
End-stage kidney disease; dialysi; glucose-sparing; kidney failure-solution; l-carnitine; peritoneal dialysi; xylitol |
| Description: |
Peritoneal dialysis adoption and technique survival is affected by limitations related to peritoneal membrane longevity and metabolic alterations. Indeed, almost all peritoneal dialysis fluids exploit glucose as an osmotic agent that rapidly diffuses across the peritoneal membrane, potentially resulting in metabolic abnormalities such as hyperglycemia, hyperinsulinemia, obesity, and hyperlipidemia. Moreover, glucose-degradation products generated during heat sterilization, other than glucose itself, induce significant morphological and functional changes in the peritoneum leading to ultrafiltration failure. The partial substitution of glucose with osmotic agents characterized by a better local and systemic biocompatibility has been suggested as a potential strategy to innovate peritoneal dialysis fluids. The approach aims to minimize glucose-associated toxicity, preserving the peritoneal membrane welfare and counteracting common comorbidities. In this work, we report the clinical trial design of ELIXIR, a phase III randomized, controlled, blinded outcome assessment study comparing Xylocore®, an innovative formulation based on Xylitol and l-carnitine, to standard glucose-based regimens, in end-stage kidney disease patients treated with continuous ambulatory peritoneal dialysis; 170 patients will be randomized (1:1) to receive XyloCore® or to continue their pre-randomization peritoneal dialysis (PD) therapy with glucose-only PD solutions, for 6 months. The primary study's objective is to demonstrate the noninferiority of XyloCore® in terms of Kt/V urea, for which a clinically acceptable noninferiority margin of −0.25 has been determined, assuming that all patients will be treated aiming to a minimum target of 1.7 and an optimal target of 2.0. |
| Document Type: |
article in journal/newspaper |
| File Description: |
ELETTRONICO |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/39205396; info:eu-repo/semantics/altIdentifier/wos/WOS:001301070400001; volume:45; issue:1; firstpage:17; lastpage:25; numberofpages:9; journal:PERITONEAL DIALYSIS INTERNATIONAL; https://hdl.handle.net/11564/837892 |
| DOI: |
10.1177/08968608241274106 |
| Availability: |
https://hdl.handle.net/11564/837892; https://doi.org/10.1177/08968608241274106; https://journals.sagepub.com/doi/10.1177/08968608241274106 |
| Rights: |
info:eu-repo/semantics/closedAccess |
| Accession Number: |
edsbas.5CBF2F86 |
| Database: |
BASE |